

# Andreas Viardot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2199961/publications.pdf>

Version: 2024-02-01

24  
papers

5,845  
citations

567281

15  
h-index

580821

25  
g-index

26  
all docs

26  
docs citations

26  
times ranked

5848  
citing authors

#	ARTICLE	IF	CITATIONS
1	Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 326-334.	1.3	3
2	Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 561-571.	1.8	3
3	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. <i>Leukemia and Lymphoma</i> , 2022, 63, 2063-2073.	1.3	9
4	A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021, 137, 2646-2656.	1.4	39
5	Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 1077-1087.	1.3	13
6	Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 773-784.	4.1	8
7	First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL). <i>Blood</i> , 2021, 138, 362-362.	1.4	12
8	Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2767-2770.	1.3	14
9	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. <i>Annals of Hematology</i> , 2020, 99, 2215-2229.	1.8	29
10	&lt;p&gt;Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2393-2404.	1.9	14
11	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 2271-2281.	13.7	155
12	Bispecific antibodies in haematological malignancies. <i>Cancer Treatment Reviews</i> , 2018, 65, 87-95.	7.7	55
13	Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG). <i>Blood</i> , 2018, 132, 448-448.	1.4	6
14	Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 127, 1410-1416.	1.4	295
15	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1104-1111.	1.6	359
16	Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. <i>Blood</i> , 2015, 126, 2578-2584.	1.4	136
17	Phase II Trial of the Anti-CD19 Bispecific T Cellâ€Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 4134-4140.	1.6	577
18	PI3KÎ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	27.0	956

#	ARTICLE	IF	CITATIONS
19	Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-€engaging CD19/CD3-bispecific BiTE antibody blinatumomab. <i>Blood</i> , 2012, 119, 6226-6233.	1.4	410
20	Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. <i>Blood</i> , 2012, 120, 5185-5187.	1.4	435
21	Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. <i>Blood</i> , 2012, 120, 2032-2041.	1.4	381
22	High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. <i>Blood</i> , 2011, 118, 3504-3511.	1.4	158
23	Targeted Therapy With the T-Cell-€Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival. <i>Journal of Clinical Oncology</i> , 2011, 29, 2493-2498.	1.6	819
24	Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-€Engaging Antibody. <i>Science</i> , 2008, 321, 974-977.	12.6	957